Detalles de la búsqueda
1.
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Br J Haematol
; 204(1): 250-259, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37784256
2.
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Cancer
; 129(17): 2645-2654, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269074
3.
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
Eur J Haematol
; 106(5): 708-715, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33580608
4.
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.
Biol Blood Marrow Transplant
; 25(10): 2008-2016, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31271884
5.
Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Br J Haematol
; 177(5): 759-765, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28369779
6.
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
Blood
; 118(5): 1231-8, 2011 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21652683
7.
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.
Lancet Haematol
; 9(2): e121-e132, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34906334
8.
Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant
; 57(10): 1514-1519, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35773347
9.
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
Bone Marrow Transplant
; 57(8): 1269-1276, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568756
10.
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT.
Bone Marrow Transplant
; 56(2): 481-491, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32892216
11.
Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).
Cancer Med
; 10(1): 23-33, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242374
12.
Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission.
Ann Hematol
; 89(5): 505-12, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19876629
13.
Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.
Bone Marrow Transplant
; 55(10): 1975-1984, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203258
14.
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Lancet Haematol
; 4(7): e310-e316, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28566209
15.
The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants.
Biol Blood Marrow Transplant
; 13(5): 550-9, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17448914
16.
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Br J Haematol
; 136(5): 752-61, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17313378
17.
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
Blood
; 110(13): 4614-7, 2007 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17881635
18.
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.
Br J Haematol
; 123(3): 479-83, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14617010
Resultados
1 -
18
de 18
1
Próxima >
>>